Nice time line there Torpy, good to see the detailed progression - thanks.
Definitely illustrative of just how much body of work needs to be done to get us eventually to commercialisation! It spans years.
The good news is that they don't have to do the same repetitive work for each and every strain of MPS and in fact the higher and broader classification of Lysosomal Diseases. Once they get enough evidence for a couple of these strains linked together, it should be enough to formulate a Phase 3 (in my view) and that will be the eventual path to registration. I hold probably around 10% chance that we may get this phase three opened at some point but not sure on the chance of that.
As it is novel drug (though repurposed) we may need to prove it in the larger number set in a full length P3? It would be ideal if half way through such a P3 if we reach a tipping point and the FDA say we can start selling as long as we keep the P3 going meanwhile? Its these sort of surprise elements that are so completely NOT factored into our share price, let alone the whole MPS indication as a meaningful future revenue stream.
- Forums
- ASX - By Stock
- PAR
- What do they want?
What do they want?, page-6
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 11571 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 0.245 |
8 | 120363 | 0.240 |
5 | 126753 | 0.235 |
5 | 146782 | 0.230 |
2 | 53000 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 11571 | 1 |
0.260 | 15236 | 1 |
0.265 | 59987 | 2 |
0.270 | 10000 | 1 |
0.275 | 16347 | 3 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online